Postoperative Pain
Conditions
Brief summary
Breast cancer is the most diagnosed type of cancer in women in Turkey and in the world. According to the World Health Organization data, the rate of newly diagnosed breast cancer was reported as 11.6% in 20181. Acute postoperative pain occurs in 40% of patients undergoing surgery for breast cancer2. In the early postoperative period, opioids are commonly used analgesics in the treatment of pain, but they have various side effects such as gastrointestinal, urinary and respiratory symptoms3. Non-opioid analgesics can be used to reduce opioid use and thus limit its side effects. Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9. The primary aim of this study is to investigate the postoperative analgesic efficacy of MgSO4 in patients who were scheduled for mastectomy with the diagnosis of breast cancer. The secondary aim of our study is to evaluate the changes in perioperative vital signs that may occur due to MgSO4.
Interventions
DRUGMagnesium Sulfate
Magnesium sulfate (MgSO4) is an N-Methyl D-Aspartate (NMDA) receptor antagonist that has been used for postoperative analgesia and reducing both the duration and intensity of pain by preventing central sensitization in response to peripheral painful stimulus4-9.
DRUGnormal saline isotonic solution
only 250 ml of normal saline isotonic solution 30 minutes before induction,
Sponsors
Pamukkale University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Female breast cancer patients scheduled for mastectomy and modified radical mastectomy 2. 18≥ years and 3. Patients with ASA score I-II
Exclusion criteria
1. The patient who refused the study 2. Drug allergy 3. Unregulated diabetes mellitus and hypertension 4. Cardiac failure with \<45% ejection fraction 5. Renal failure (serum creatinine \> 2 mg/dL) 6. Liver failure (blood transaminase values 2 fold higher than normal) 7. Glaucoma 8. Psychiatric or neurological disorders 9. Communication difficulties with patient 10. Calcium channel blockers or narcotic drugs uses before surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative pain was measured and recorded with the Verbal Numeric Rating Scale | 24 hours | Postoperative pain was measured and recorded with the Verbal Numeric Rating Scale (VNRS) (0 no pain-10 very pain). |
Countries
Turkey (Türkiye)
Outcome results
None listed